Skip to content
Faucet hero 2400x1350-blank-right-offset Faucet hero 2400x1150-blank-mobile2

Hearing Nothing Doesn't Mean Nothing's Happening

Are your patients still on BPH meds?

They may be silently suffering. Intervening earlier with treatments that address the blockage may preserve bladder health.6 Partner with UroLift-trained urologists in your area to support a faster care pathway.

Locate UroLift-Trained Urologists

Are you frustrated by medication nonadherence and the challenges of polypharmacy?

50
%

About half of men surveyed are dissatisfied with their BPH medication.3

71
%

Up to 71% of patients are non-adherent with their BPH meds after one year.4

48
%

Of men on BPH medications experience <4 point IPSS symptom improvement5

Help Your Patients Preserve Bladder Health

Impact on wellbeing
Quality of life and overall health are important considerations in treating men with BPH. Watchful waiting can risk long-term bladder health.6 The use of BPH medications may be associated with potential side effects,7 and many men are dissatisfied with the effectiveness of their BPH medication in relieving symptoms.3,5

 

Bladder Disease Progression from a healthy bladder to a permanently damaged bladder

“Since many men discontinue medical therapy, yet proportionately few seek surgery, there is a large clinical need for an effective treatment that is less invasive than surgery.”

American Urological Association BPH Guidelines 2023

The UroLift™ System Advantage

A mechanical solution to a mechanical problem

The UroLift™ System uses a proven approach to treating BPH that lifts and holds the enlarged prostate tissue out of the way, so it no longer blocks the urethra. It is the leading transurethral BPH treatment that does not require heating, cutting or removal of the prostate tissue.13,14 Post-procedure, most patients do not require ongoing BPH medications.15

Refer your appropriate patients to a urologist who can determine if they are a candidate for the UroLift™ System.

The UroLift™ System reopens the channel—with no cutting or burning of the prostate.

Common Questions Your Patients May Ask

Icon of a magnifying glass

What’s the harm in watchful waiting?

87% of men who elect watchful waiting reported a worsening of symptoms over a 4-year period.9

Icon of a pill with a cancel symbol

Can I continue taking my BPH medications forever? 

Some BPH medications have been associated with serious issues, such as increased risk of cardiac failure and impaired cognitive function.1,2,10

Icon of two people in bed

What about sexual function?

UroLift™ System patients reported better outcomes in sexual function* and satisfaction than men who received BPH medication.12

Silhouette of a person with a speech bubble

Connect with a Teleflex representative to learn more and get resources for your staff and patients.

Icon of a checklist

Download an IPSS form to help identify patients who may benefit from the UroLift™ System treatment.

Man holding a pill bottle while talking to a doctor
“It is our responsibility to educate the patient about all the options. Many of my patients prefer the UroLift™ System procedure over a pill.”
Dr. Robert Cowles+
“I’m extremely satisfied and eternally grateful for the great outcome. It was absolutely worth it. I’d do it again in a heartbeat.”
Steve K, 63
Steve K., "Mr. Gadget" wanted to stop taking BPH medications.
Read Steve's Story
Icon of a bar chart

Review the Clinical Data

Data from 145 peer-reviewed and 22 sponsored publications about the UroLift™ System.

Learn More
peer-icon

Get Patient Perspectives

Watch videos and read blogs about real-life experience with the UroLift System.

Learn More
Icon of a cursor clicking

BPH Advisor

Patients can take a short quiz to get a personalized, detailed BPH report and receive helpful articles by text or email.

Learn More

References

  • 1.  Duan, Pharmacoepidemiol Drug Saf 2018 

  • 2.  Welk, J Neurol Sci 2017

  • 3. Survey of US men aged 40+ who have been diagnosed with BPH (enlarged prostate) and are/have been treated with BPH medications, conducted by Teleflex in 2020. Data on file, n=96.

  • 4. Cindolo, Eur Urol 2015

  • 5. Wei, et al, 2010 Abstract

  • 6. Flanigan, J Urol 1998

  • 7. AUA Guidelines 2003

  • 8. Tubaro, Drugs Aging 2003

  • 9. Djavan, Urology 2004

  • 10. Lusty, J Urol 2021

  • 12. Roehrborn, Eur Urol Focus 2021

  • 13. Roehrborn, J Urol 2013

  • 14. AUA Guidelines 2003, 2020

  • 15. Roehrborn, Can J Urol 2017

  • *Based on an indirect comparison of erectile and ejaculatory function and sexual satisfaction in men who received PUL in controlled studies or in men who received medical therapy in the MTOPS study.

  • + Dr. Robert Cowles was previously a paid consultant of Teleflex

MAC03180-01 Rev A